Prevalence and other epidemiological feature
PH is considered as a rare primary headache disorder. It is suggested that cases of PH are probably overlooked or underreported [
4]. PH was first described in 1974 [
5]. In the first 15 yrs (up to 1989), a total 84 cases of PH were reported in the literature [
6]. However, in the next 10 years (up to 1998), only 27 cases were reported [
7]. In 2002, Boes and Dodick reported 74 patients with CPH (Goadsby and Lipton’s criteria) [
2]. Isolated PH cases are no longer reported now days [
4]. However, the literature is scarce even for larger case series. During the last 12 years, only one large case series (31 patients) has been reported [
8]. These suggest that cases of PH are underreported or overlooked.
In the early years, the prevalence of PH was estimated in relation to the prevalence of CH, and it was 0.9 to 3% [
6]. This estimation was done by Antonaci and Sjasstad in 1989 (within the first 15 yrs of the discovery of the first case of PH) [
6]. The authors predicted “this ratio may change considerably in the foreseeable future”. After 1989, we noted at least two studies where PH was compared to CH. In 2002, Faud and Jones [
9] reported 11 patients with PH. In parallel, they reported 30 patients with CH over the same period. The ratio of PH to CH was 30%. In the same way, this ratio was 15% in Zidverc-Trajkovic et al. study [
10]. According to these two studies, the prevalence of PH (with respect to CH) may be more than 15% of CH. This indicates that PH is probably more common than it was anticipated earlier. Seidel et al. [
11] reported 63 consecutive patients with unilateral headache not resembling migraine or CH. Only twenty-four patients received a diagnosis of primary headache disorders. Six of them had PH. Blankenburg [
12] reported 8 children with PH among 628 children (1.3%) with chronic daily headache and suggested that PH is under diagnosed even in children. A possibility of misdiagnosis also exists. Initially, PH was considered as a disease of the female (2.3 to 7: 1) [
4]. However, in Cittadini case series (31 patients), female preponderance was not obvious. The authors suggested that it may be because of mis-diagnosis of males with PH as cluster headache, as it is the more common with a distinct male preponderance. Our all patients were never diagnosed previously before reporting to us. This suggests that a possibility of mis-diagnosis or unawareness to PH may be very high.
Taken together, PH is probably an under diagnosed and underreported primary headache disorder. We observed 17 patients with PH (and 5 probable PH) over 6 years duration. Our case series is probably the third largest case series in the literature.
The mean age of onset (38 yrs) was comparable to other studies. In Cittadini et al. series [
8], it was 37 yrs and in a review of 84 patients, mean age was 34 yrs [
6]. PH is classically considered as a disease with female preponderance. However, in Cittadini et al. series [
8], male outnumbered female (17 vs 14). In our series male: female was 1:1.1 (8 male vs 9 female). These two observations suggest that both male and female may be equally affected.
Duration and frequency of attacks
Seventeen patients fulfilled the criteria for PH. The closet differential diagnosis of PH is CH [
4]. Clinical characteristics for both PH and CH is similar. PH is usually distinguished from other TACs by the duration and frequency of attacks and by a response to indomethacin in patients with PH [
1,
4]. However, as there is overlap in the diagnostic criteria for PH and CH, a possibility of misdiagnosis always exist in patients with PH and vice-versa [
8,
13]. Presence of indomethacin responsive CH may further complicate the issue [
13].
In our all 17 cases of (typical) PH, duration and frequency of attacks were more compatible with the diagnosis of PH. All patients had headache duration between 5–30 minutes (as defined in the ICHD-II criteria for PH). Only four patients (24%) had a few headache attacks of more than 30 minutes. In Cittadini et al. series [
8], 55% patients had the longest attack duration of more than 30 min. In Boes and Dodick case series [
2], the maximum attack duration was more than 60 minutes in 41% patients. A patient may have a few attacks of many hours. This indicates that a few attacks in a patient may be more than of 30 minutes (an upper limit defined in ICHD-II criteria for PH). This may create diagnostic confusion, and a misdiagnosis as CH or migraine exists if patient or physician focuses mainly on maximum attack duration. Therefore, mean or average duration of the attacks should be considered in making the diagnosis of PH and other TACs.
In the same way, the frequency of attacks is also an important point in making the diagnosis of PH. More than 5 attacks per day for more than half of the time is essential to make the diagnosis of PH. All 17 patients (typical PH) fulfilled this criterion. The maximum attack frequency was ≥ 10 / day in all 17 patients. However, we observed 2 more patients who never had 5 or more attacks in a day. Other clinical features, including response to indomethacin were according to the ICHD-II criteria for PH. We considered these two patients as atypical PH. Although ICHD-II acknowledges the presence of lower frequency in patients with PH, ≥ 5 / day for more than half of the time is must to fulfill the criteria. In review of the literature, we noted a number of patients with the maximum attack frequency of < 5 / day. The maximum attack frequency was between 2 and 5 in 37% patients in Boes and Dodick case series [
2]. In Cittadini case series [
8], at least three patients had a maximum attack frequency of less than five in a day. In Zidverc-Trajkovic et al. observations [
10], two patients (out of eight patients) had attack duration shorter than proposed by ICHD-II criteria. These observations suggest that a few patients may never have attack frequency of more than 5 in a day.
Cranial autonomic features
Patients with PH are required to have at least one of the cranial autonomic features according to ICHD-II criteria. Our three patients (16%) never had autonomic features. Two (4%) patients in Boes and Dodick case series [
2] had no autonomic features. One patient in Cittadini case series had not any classical autonomic features and reported only a sense of ear fullness during the attacks. Maggioni [
3] reported a case of episodic PH with no cranial autonomic feature and suggested a possibility of a subgroup of PH. Similar observations have also been noted in patients with CH and HC. Three to seven percent patients with CH may never have cranial autonomic features during CH attacks [
14]. Various case series suggest that a large number of patients with HC may never have autonomic feature during the exacerbation of attacks [
15]. Feeling of sand or itching in eye is classically described as an autonomic feature in patients with HC [
15]. Our 8 patients (47%) mentioned the feeling of sand or itching in eye during the headache episodes. These observations need to be confirmed prospectively in other case series.
It is suggested that the presence of autonomic features is related to the intensity of the headaches [
14]. Autonomic features are less likely to occur in patients with moderate to severe rather than excruciating attacks of pain. As the intensity of pain attacks in PH is much less than attacks of CH, absence of autonomic feature is possible even in patients with PH. ICHD-II acknowledges the diagnosis of CH in the absence of cranial autonomic features ( if patient has restlessness) [
1]. The similar suggestion has been given even for making the diagnosis of HC (i.e. HC should be diagnosed even in the absence of cranial autonomic feature) [
15]. Therefore, we suggest that ICHD-II should acknowledge the diagnosis of PH even in the absence of autonomic symptoms.
Restlessness/agitation
Restlessness or agitation is classically described in patients with CH and it is one of the components of the ICHD-II diagnostic criteria for CH. It provides an alternative to make the diagnosis of CH even in the absence of autonomic feature. A few authors suggest that restlessness or agitation should also be included in the diagnostic criteria for HC [
15,
16]. Review of the literature suggests that restlessness or agitation may be noted in 50-90% of patients with PH. Our 76% reported restlessness or agitation. We suggest that like CH, restlessness / agitation should be included in the diagnostic criteria for PH, as it would provide alternative to make the diagnosis of PH in the absence of autonomic feature.
Lack of complete indomethacin response
A response to indometacin is considered as a
sine qua non in PH. Our one patient had an incomplete response to indomethacin. In Boes and Dodick case series [
2], 25% (10/40) patients did not exhibit responses to indomethacin. A few other patients (6 patients) had only a partial response to indomethacin. In the other two patients, a complete response to indomethacin was not sustained.
HC is another indomethacin responsive primary headache disorder. However, recent observations indicate that the indomethacin resistant HC is a distinct possibility [
15,
17,
18]. In an earlier review, we suggested a possibility of under reporting of HC unresponsive to indomethacin, as it is difficult to classify such patients according to the present ICHD-II classification [
18]. The same possibility may exist for PH unresponsive to indomethacin and it may be the reason for underreporting of PH in the literature. In a review, we noted that CH may be wrongly diagnosed as PH if patients with CH show a response to indomethacin [
13]. Therefore, a possibility exists that PH unresponsive to indomethacin (especially borderline cases) can be diagnosed as CH. As the prevalence of CH is very high than PH, a possibility of misdiagnosis of PH as CH is more likely (than CH diagnosed as PH). Patients with PH also show response to lithium, verapamil, and topiramate. Therefore, a patient will not receive the diagnosis of PH, if a patient shows a response to another drug before a trial to indomethacin. Our five patients (29%) showed a partial response to lithium and verapamil (before a trial of indomethacin), and were labeled as CH. Prospectively our 2 patients showed a response to topiramate.
Interictal pain
Eight of 17 patients (47%) reported interictal pain. Seven of these (88%) had intermittent pain. This interparoxysmal pain was usually mild and was mainly described as discomfort in that area. The presence of interictal pain may create diagnostic confusion with HC [
15]. However, “mild” and “intermittent” nature of interparoxysmal pain favors the diagnosis of PH. Moreover, frequency and duration of attacks were more compatible with the diagnosis of PH. Frequency and duration of the exacerbations in patients with HC are highly variable and duration of attacks frequently crosses the upper defined levels of PH (and CH) [
15]. The exacerbations in a patient with HC vary between a few minutes to many hours (may be upto days) [
15]. One patient reported continuous inteictal pain. The interictal pain was mild, and periodic exacerbations matched with the frequency and duration described for PH. Moreover, the patient did not have interictal pain during the early years of the disease.
We compared patients with interictal pain to patients with no such pain. The mean duration of illness was significantly higher in patients with interictal pain (69.0 vs 10.7 months, p = 0.0006). In the same way, patients with interictal pain required a high dose of indomethacin (188 vs 114 mg, p = 0.0018). These observations indicate that patients with longer duration of history are more likely to have interictal pain and these patients may require higher doses of indomethacin. Such type of observations was also noted in patients with CH [
19]. In Marmura et al’s case series [
19], patients with a long history of disease were more likely to have interictal pain. The patients with a long history of disease and interictal pain were more refractory to the therapy. Various mechanisms have been suggested for these observations. It is said that any longstanding chronic pain may lead to cortical changes in the brain and it may be responsible for the interictal pain and refractoriness to therapy [
19‐
21]. As these patients may require higher doses of indomethacin, an early diagnosis is very important.
Taken together, our case series and review of the literature suggest that a subgroup of patients may not fulfill the all the features of ICHD-II diagnostic criteria of PH and a possibility of a subgroup of PH exist. Therefore, we suggest the inclusion of a more accommodating alternative diagnostic criteria or probable PH in the appendix section.
There are marked overlap in clinical features and therapeutic responses among TACs. Clinical features and therapeutic responses in patients with HC also overlap with TACs. Most pathophysiological studies on TACs have been done in CH. The literature is relatively sparse on PH, SUNCT, and HC. However, it is also suggested that all three TACs and HC have common pathophysiology [
22]. In the absence of clear cut biological marker, it will be difficult to differentiate borderline or atypical cases of TACs and HC. In Seidel et al. [
11] case series of 63 consecutive patients with unilateral headache not resembling migraine or CH, only twenty-four patients (38%) received a diagnosis of primary headache disorders. Headaches could not be classified according to present ICHD-II criteria in 49% patients. This suggests that there is need of refinement of diagnostic criteria of PH and other unilateral headache disorders.
Migraine is the best studied primary headache disorder with well defined pathophysiology. In spite of these, ICHD-II has provided an alternative diagnostic criterion in the appendix section. In the same way, there is need of alternative diagnostic criteria of various other primary headache disorders, including PH. Therefore, till we get biological marker of PH or other TACs, it will be better to have more accommodating type of criteria in the appendix section so that we can refine rare primary headache disorders in the future.
Limitations of our observations
This is a retrospective study and a possibility of unrecognized selection bias and recall bias exists. Although we included only those patients who had normal neuroimaging, we cannot rule out secondary headaches, as full evaluation for secondary headache was not performed on each patient. In addition, we did not have the facilities to do ‘indotest’. Our observation did not have large enough numbers to reveal true differences between the typical PH (ICHD-II fulfilled) and atypical PH. Despite these limitations, our observations and review of the literature suggests that a few patients may not fulfill all the ICHD-II criteria for PH and there is need for refinement of the criteria.